Why are the phase III results important?

  • An expert interviewed by Bernstein called the phase III melanoma results for the personalized mRNA vaccine intismeran a transformative advance: cancer vaccine studies have often shown immune responses in the past but lacked clear clinical benefit; this time, clinically meaningful benefits were shown in recurrence-free survival and distant metastasis-free survival.
  • The comparator was pembrolizumab, which is already used in treatment, rather than observation alone. The expert placed particular weight on distant metastasis-free survival because distant metastasis directly threatens the survival of patients with melanoma.
  • Based on clinical experience, the expert believes the absolute gap in distant metastasis-free survival could widen with longer follow-up; more mature data are still needed for the final overall survival results.

Which patients are most likely to receive the vaccine?

  • The most immediate opportunity is to add the vaccine for patients who have already chosen postoperative adjuvant PD-1 therapy, rather than substantially expanding the overall population receiving adjuvant treatment. The expert believes the combination may improve efficacy, but the risk of immune-related toxicity remains because it still includes pembrolizumab.
  • Willingness to use treatment varies by recurrence risk and stage. The expert estimates that about 50% of stage IIB/IIC patients at their academic medical institution receive adjuvant therapy, compared with about 30% in US community medical institutions; the figure exceeds 70% for stage IIIB and above, while only a minority of stage IIIA patients receive treatment. These are estimates based on personal practice.
  • The trade-off is particularly difficult for lower-risk patients: some stage II patients can be cured by surgery alone, while PD-1 therapy can cause severe immune toxicity. Factors such as tumor thickness, ulceration and lymph node disease burden also influence treatment decisions.

Will the vaccine change existing treatment pathways?

  • The expert expects the vaccine to serve mainly as a complement to postoperative adjuvant therapy. Patients with visible tumors or lymph node involvement at presentation may be considered for preoperative neoadjuvant immunotherapy; patients whose risk becomes apparent only after surgery and sentinel lymph node staging are the main population for postoperative vaccination.
  • The expert estimates that about one-quarter of the relevant early-stage patients are candidates for neoadjuvant treatment. Future use of the vaccine after neoadjuvant therapy would need to address the timing of tissue sampling, the effect of prior immunotherapy on neoantigens, and whether the manufacturing cycle can fit the treatment schedule.
  • If the vaccine is approved, the expert believes it could increase pembrolizumab's share of adjuvant PD-1 treatment because the combination regimen is based on that drug.

What else could constrain a move from clinical results to widespread use?

  • Personalized manufacturing requires retrieving pathology tissue, sending it to a central laboratory, completing quality control and then manufacturing a vaccine individually for each patient. The expert believes academic institutions can carry this out, but broader use in routine care will also require reliable tissue tracking, quality-control status information and predictable manufacturing times.
  • Community hospitals may adopt it more slowly than academic centers: community oncologists must cover multiple cancers and also face staffing, billing and administrative burdens; insurance reimbursement and patient acceptance of the vaccine will also affect adoption.
  • Other cancers still need their own clinical validation. Melanoma responds particularly well to immunotherapy, and the expert believes its results and associated biomarkers cannot be used directly to predict efficacy in other tumors; neoantigen selection, formulation design and administration methods across vaccine platforms may also affect results.